Opinion|Videos|March 13, 2025
Dr. Galsky’s Perspectives on the CheckMate 274 Data Results
Author(s)Matthew Galsky, MD
An expert discusses how recent data on adjuvant anti–PD-1 trials highlight the significance of disease-free survival (DFS) and overall survival (OS), guiding clinical decisions. In muscle-invasive urothelial carcinoma (MIBC), event-free survival (EFS) and OS benefits without delaying curative cystectomy are crucial. Adjuvant nivolumab is typically initiated within 12 weeks post cystectomy, considering pathology, recovery, and performance status.
Episodes in this series
Video content above is prompted by the following:
- What are your perspectives on the data, and what has been learned? How are you applying these results to your practice?
- To what degree do you consider the benefit regarding DFS vs OS in adjuvant anti–PD-1 trials?
- What is the importance of EFS and OS benefit with no associated delay in curative intent radical cystectomy for your patients with MIBC?
- What is the time window in patients after radical cystectomy prior to initiating adjuvant nivolumab (if no metastases)? Which factors inform your decision?
